FDA moves to strike suicide risk warnings from 3 GLP-1s

The FDA is requesting that drugmakers remove suicidal ideation and behavior warnings from the labeling of three GLP-1 receptor agonists — Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide) — effective Jan. 13, 2026. The FDA’s decision follows a meta-analysis of 91 placebo-controlled trials comprising 107,910 patients, according to a Jan. 13 FDA news release. Of […]

Correction: Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut–pancreas–liver axis

Food Funct., 2026, Advance ArticleDOI: 10.1039/D6FO90005D, Correction Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Hong Hu, Jie Luo, Ying Liu, Hongyu Li, Rui Jin, Shengjie Li, Jing Wei, Hong Wei, Tingtao ChenTo cite this article before page numbers are assigned, use the DOI form of citation above.The […]

Popular weight-loss drugs shouldn’t carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk’s […]

Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]   SAN FRANCISCO — Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently […]